Dogwood Therapeutics, Inc.
For the period ended Mar 26, 2026. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 26, 2026 · Filed Mar 26, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Progress Report
Progress Report
ALPHARETTA, Ga., March 26, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a development-stage biotechnology company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today issued a corporate update in the following Letter to Shareholders from CEO Greg Duncan.
Dear Shareholders,
Dogwood Therapeutics is a development-stage biotechnology company with the ultimate goal of advancing the standard of care for patients suffering from cancer-related pain and neuropathy, two conditions where both patients and providers are in clear need of alternative treatment options. As we exit the first quarter of 2026, the Company has made extensive progress over the past quarter in expanding and advancing its pipeline of first-in-class new development candidates to treat cancer- and chemotherapy-induced pain and neuropathy.
Highlights include:
| ● | Recruitment of 145 patients in the Halneuron® Phase 2b Chemotherapy Induced Pain (HALT-CINP) Study, with final study data projected for release this fall. |
| ● | Raised $12.5 million in capital this quarter, which, when combined with our 2025 year-end cash on hand, provides operational runway through the Halneuron® HALT-CINP data release this fall. |
| ● | Filed the investigational new drug application for SP16 IV, a potential treatment for neuropathy and inflammation caused by cancer chemotherapy. The license is a royalty-free, global development and commercialization license to treat cancer-related pain and neuropathy. |
| o | The forthcoming SP16 Phase 1b study is fully funded by a development grant from the National Cancer Institute. |
| ● | Continued advanced development of a chemically equivalent, synthesized version of Halneuron® to be used for Phase 3 development and commercialization. |
| o | This new formulation should reduce manufacturing costs and improve yields as compared to the current biological extract. |
As a team, we believe the year ahead holds great promise for DWTX shareholders and patients alike. In 2026, we are focused on executing on the following target milestones:
| ● | Filing the SP16 Chemotherapy Induced Pain and Neuropathy Investigational New Drug application (IND) with FDA in collaboration with our partner, Serpin Pharma, in the first quarter. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.